Second European evidence-based consensus on the diagnosis and management of ulcerative colitis Part 3: Special situations

Journal of Crohn's and Colitis

Volumn 7, Issue 1, 2013, Pages 1-33

  Van Assche, Gert ^a   Dignass, Axel ^b   Bokemeyer, Bernd ^c   Danese, Silvio ^c   Gionchetti, Paolo ^c   Moser, Gabriele ^c   Beaugerie, Laurent ^c   Gomollón, Fernando ^c   Häuser, Winfried ^c   Herrlinger, Klaus ^c   Oldenburg, Bas ^c   Panes, Julian ^c   Portela, Francisco ^c   Rogler, Gerhard ^c   Stein, Jürgen ^c   Tilg, Herbert ^c   Travis, Simon ^c   Lindsay, James O ^c  

^a UNIVERSITY HEALTH NETWORK   (Canada)

^b AGAPLESION MARKUS KRANKENHAUS   (Germany)

^c NONE

Author keywords

Anaemia; Colorectal cancer surveillance; Extraintestinal manifestations; Pouchitis; Psychosomatic; Ulcerative colitis

Indexed keywords

ACETYLSALICYLIC ACID; ADALIMUMAB; ALICAFORSEN; AMOXICILLIN PLUS CLAVULANIC ACID; AZATHIOPRINE; BISPHOSPHONIC ACID DERIVATIVE; BUDESONIDE; CALCINEURIN INHIBITOR; CALCITONIN; CELECOXIB; CERTOLIZUMAB PEGOL; CIPROFLOXACIN; CORTICOSTEROID; CYCLOSPORIN A; ENEMA; ETORICOXIB; INFLIXIMAB; MESALAZINE; METHOTREXATE; METRONIDAZOLE; NONSTEROID ANTIINFLAMMATORY AGENT; PARATHYROID HORMONE[1-34]; RALOXIFENE; RIFAXIMIN; SALAZOSULFAPYRIDINE; STRONTIUM RANELATE; TINIDAZOLE; UNINDEXED DRUG; URSODEOXYCHOLIC ACID; VSL3;

ABSCESS; ACUTE DISEASE; ACUTE FEBRILE NEUTROPHILIC DERMATOSIS; ACUTE POUCHITIS; ADENOCARCINOMA; ANEMIA; ANKYLOSIS; ANTIBIOTIC THERAPY; ANXIETY; ARTHRITIS; ARTHROPATHY; BONE DENSITOMETRY; BONE DENSITY; BONE MASS; CANCER PROGNOSIS; CANCER RISK; CANCER SCREENING; CHROMOENDOSCOPY; CHRONIC DISEASE; CHRONIC INFLAMMATION; CHRONIC POUCHITIS; CLOSTRIDIUM DIFFICILE; COLON BIOPSY; COLON RESECTION; COLONOSCOPY; COLORECTAL CANCER; COLORECTAL CARCINOMA; CONSENSUS; CUFFITIS; DEPRESSION; DIFFERENTIAL DIAGNOSIS; DISEASE ACTIVITY; DISEASE COURSE; DISEASE DURATION; DRUG MEGADOSE; DRUG TREATMENT FAILURE; ENDOSCOPY; EPISCLERITIS; ERYTHEMA NODOSUM; EUROPE; FRACTURE; HEALTH CARE UTILIZATION; HEART DISEASE; HEPATOBILIARY DISEASE; HISTOPATHOLOGY; HUMAN; ILEITIS; ILEOSTOMY; ILEUM CANCER; INFLAMMATORY BOWEL DISEASE QUESTIONNAIRE; INTERPERSONAL COMMUNICATION; INTESTINE BIOPSY; INTESTINE FISTULA; INTESTINE OBSTRUCTION; INTESTINE VILLUS ATROPHY; LACTOBACILLUS PLANTARUM; LIVER DISEASE; MENTAL STRESS; META ANALYSIS (TOPIC); METABOLIC BONE DISEASE; NAMED INVENTORIES, QUESTIONNAIRES AND RATING SCALES; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; OSTEOPENIA; OSTEOPOROSIS; POUCHITIS DISEASE ACTIVITY INDEX; POUCHOSCOPY; PRIORITY JOURNAL; PROCTITIS; PROCTOCOLECTOMY; PSYCHOLOGICAL ASPECT; PSYCHOTHERAPY; PYODERMA GANGRENOSUM; QUALITY OF LIFE; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL (TOPIC); RELAXATION TRAINING; REVIEW; RISK FACTOR; SCLEROSING CHOLANGITIS; SKIN DISEASE; SYMPTOM; SYSTEMATIC REVIEW (TOPIC); ULCERATIVE COLITIS; UVEITIS; VENOUS THROMBOEMBOLISM;

ANEMIA; ANXIETY; BILIARY TRACT DISEASES; BONE DISEASES, METABOLIC; COLITIS, ULCERATIVE; COLORECTAL NEOPLASMS; DEPRESSION; EARLY DETECTION OF CANCER; EVIDENCE-BASED MEDICINE; EYE DISEASES; HUMANS; JOINT DISEASES; LIVER DISEASES; POPULATION SURVEILLANCE; POUCHITIS; SKIN DISEASES; VENOUS THROMBOEMBOLISM;

EID: 84872145972     PISSN: 18739946     EISSN: 18764479     Source Type: Journal    
DOI: 10.1016/j.crohns.2012.09.005     Document Type: Review

References (352)

1. Fazio V.W., Ziv Y., Church J.M., Oakley J.R., Lavery I.C., Milsom J.W., et al. Ileal pouch-anal anastomoses complications and function in 1005 patients. Ann Surg 1995, 222:120-127.
2. Sandborn W.J. Pouchitis following ileal pouch-anal anastomosis: definition, pathogenesis, and treatment. Gastroenterology 1994, 107:1856-1860.
3. Hurst R.D., Molinari M., Chung T.P., Rubin M., Michelassi F. Prospective study of the incidence, timing and treatment of pouchitis in 104 consecutive patients after restorative proctocolectomy. Arch Surg 1996, 131:497-500. [discussion 501-2].
4. Meagher A.P., Farouk R., Dozois R.R., Kelly K.A., Pemberton J.H. J ileal pouch-anal anastomosis for chronic ulcerative colitis: complications and long-term outcome in 1310 patients. Br J Surg 1998, 85:800-803.
5. Penna C., Dozois R., Tremaine W., Sandborn W., LaRusso N., Schleck C., et al. Pouchitis after ileal pouch-anal anastomosis for ulcerative colitis occurs with increased frequency in patients with associated primary sclerosing cholangitis. Gut 1996, 38:234-239.
6. Simchuk E.J., Thirlby R.C. Risk factors and true incidence of pouchitis in patients after ileal pouch-anal anastomoses. World J Surg 2000, 24:851-856.
7. Shen B., Fazio V.W., Remzi F.H., Lashner B.A. Clinical approach to diseases of ileal pouch-anal anastomosis. Am J Gastroenterol 2005, 100:2796-2807.
8. Stahlberg D., Gullberg K., Liljeqvist L., Hellers G., Lofberg R. Pouchitis following pelvic pouch operation for ulcerative colitis. Incidence, cumulative risk, and risk factors. Dis Colon Rectum 1996, 39:1012-1018.
9. Svaninger G., Nordgren S., Oresland T., Hulten L. Incidence and characteristics of pouchitis in the Kock continent ileostomy and the pelvic pouch. Scand J Gastroenterol 1993, 28:695-700.
10. Penna C., Tiret E., Kartheuser A., Hannoun L., Nordlinger B., Parc R. Function of ileal J pouch-anal anastomosis in patients with familial adenomatous polyposis. Br J Surg 1993, 80:765-767.
11. Tjandra J.J., Fazio V.W., Church J.M., Oakley J.R., Milsom J.W., Lavery I.C. Similar functional results after restorative proctocolectomy in patients with familial adenomatous polyposis and mucosal ulcerative colitis. Am J Surg 1993, 165:322-325.
12. Dozois R.R., Goldberg S.M., Rothenberger D.A., Utsunomiya J., Nicholls R.J., Cohen Z., et al. Restorative proctocolectomy with ileal reservoir. Int J Colorectal Dis 1986, 1:2-19.
13. Marcello P.W., Roberts P.L., Schoetz D.J., Coller J.A., Murray J.J., Veidenheimer M.C. Long-term results of the ileoanal pouch procedure. Arch Surg 1993, 128:500-503. [discussion 503-4].
14. Sagar P.M., Pemberton J.H. Ileo-anal pouch function and dysfunction. Dig Dis 1997, 15:172-188.
15. Shen B., Achkar J.P., Lashner B.A., Ormsby A.H., Remzi F.H., Bevins C.L., et al. Endoscopic and histologic evaluation together with symptom assessment are required to diagnose pouchitis. Gastroenterology 2001, 121:261-267.
16. Shen B., Lashner B.A., Bennett A.E., Remzi F.H., Brzezinski A., Achkar J.P., et al. Treatment of rectal cuff inflammation (cuffitis) in patients with ulcerative colitis following restorative proctocolectomy and ileal pouch-anal anastomosis. Am J Gastroenterol 2004, 99:1527-1531.
17. Tytgat G.N., van Deventer S.J. Pouchitis. Int J Colorectal Dis 1988, 3:226-228.
18. Pemberton J.H. The problem with pouchitis. Gastroenterology 1993, 104:1209-1211.
19. Shepherd N.A., Hulten L., Tytgat G.N., Nicholls R.J., Nasmyth D.G., Hill M.J., et al. Pouchitis. Int J Colorectal Dis 1989, 4:205-229.
20. Shen B., Achkar J.P., Lashner B.A., Ormsby A.H., Brzezinski A., Soffer E.E., et al. Irritable pouch syndrome: a new category of diagnosis for symptomatic patients with ileal pouch-anal anastomosis. Am J Gastroenterol 2002, 97:972-977.
21. Pardi D.S., Shen B. Endoscopy in the management of patients after ileal pouch surgery for ulcerative colitis. Endoscopy 2008, 40:529-533.
22. Moskowitz R.L., Shepherd N.A., Nicholls R.J. An assessment of inflammation in the reservoir after restorative proctocolectomy with ileoanal ileal reservoir. Int J Colorectal Dis 1986, 1:167-174.
23. Shepherd N.A., Jass J.R., Duval I., Moskowitz R.L., Nicholls R.J., Morson B.C. Restorative proctocolectomy with ileal reservoir: pathological and histochemical study of mucosal biopsy specimens. J Clin Pathol 1987, 40:601-607.
24. Setti Carraro P.G., Talbot I.C., Nicholls J.R. Patterns of distribution of endoscopic and histological changes in the ileal reservoir after restorative proctocolectomy for ulcerative colitis. A long-term follow-up study. Int J Colorectal Dis 1998, 13:103-107.
25. Shepherd N.A., Healey C.J., Warren B.F., Richman P.I., Thomson W.H., Wilkinson S.P. Distribution of mucosal pathology and an assessment of colonic phenotypic change in the pelvic ileal reservoir. Gut 1993, 34:101-105.
26. Ruseler-van Embden J.G., Schouten W.R., van Lieshout L.M. Pouchitis: result of microbial imbalance?. Gut 1994, 35:658-664.
27. Biancone L., Palmieri G., Lombardi A., Colantoni A., Tonelli F., Das K.M., et al. Tropomyosin expression in the ileal pouch: a relationship with the development of pouchitis in ulcerative colitis. Am J Gastroenterol 2003, 98:2719-2726.
28. Pardi D.S., Sandborn W.J. Systematic review: the management of pouchitis. Aliment Pharmacol Ther 2006, 23:1087-1096.
29. Shen B., Bennett A.E., Fazio V.W., Sherman K.K., Sun J., Remzi F.H., et al. Collagenous pouchitis. Dig Liver Dis 2006, 38:704-709.
30. Shen B., Goldblum J.R., Hull T.L., Remzi F.H., Bennett A.E., Fazio V.W. Clostridium difficile-associated pouchitis. Dig Dis Sci 2006, 51:2361-2364.
31. Bell A.J., Price A.B., Forbes A., Ciclitira P.J., Groves C., Nicholls R.J. Pre-pouch ileitis: a disease of the ileum in ulcerative colitis after restorative proctocolectomy. Colorectal Dis 2006, 8:402-410.
32. Shen B., Fazio V.W., Remzi F.H., Bennett A.E., Lopez R., Lavery I.C., et al. Effect of withdrawal of nonsteroidal anti-inflammatory drug use on ileal pouch disorders. Dig Dis Sci 2007, 52:3321-3328.
33. Landy J., Al-Hassi H.O., McLaughlin S.D., Knight S.C., Ciclitira P.J., Nicholls R.J., et al. Etiology of pouchitis. Inflamm Bowel Dis 2012, 18:1146-1155.
34. Schmidt C.M., Lazenby A.J., Hendrickson R.J., Sitzmann J.V. Preoperative terminal ileal and colonic resection histopathology predicts risk of pouchitis in patients after ileoanal pull-through procedure. Ann Surg 1998, 227:654-662. [discussion 663-5].
35. Lohmuller J.L., Pemberton J.H., Dozois R.R., Ilstrup D., van Heerden J. Pouchitis and extraintestinal manifestations of inflammatory bowel disease after ileal pouch-anal anastomosis. Ann Surg 1990, 211:622-627. [discussion 627-9].
36. Merrett M.N., Mortensen N., Kettlewell M., Jewell D.O. Smoking may prevent pouchitis in patients with restorative proctocolectomy for ulcerative colitis. Gut 1996, 38:362-364.
37. Achkar J.P., Al-Haddad M., Lashner B., Remzi F.H., Brzezinski A., Shen B., et al. Differentiating risk factors for acute and chronic pouchitis. Clin Gastroenterol Hepatol 2005, 3:60-66.
38. Carter M.J., Di Giovine F.S., Cox A., Goodfellow P., Jones S., Shorthouse A.J., et al. The interleukin 1 receptor antagonist gene allele 2 as a predictor of pouchitis following colectomy and IPAA in ulcerative colitis. Gastroenterology 2001, 121:805-811.
39. Fleshner P.R., Vasiliauskas E.A., Kam L.Y., Fleshner N.E., Gaiennie J., Abreu-Martin M.T., et al. High level perinuclear antineutrophil cytoplasmic antibody (pANCA) in ulcerative colitis patients before colectomy predicts the development of chronic pouchitis after ileal pouch-anal anastomosis. Gut 2001, 49:671-677.
40. Shen B., Fazio V.W., Remzi F.H., Brzezinski A., Bennett A.E., Lopez R., et al. Risk factors for diseases of ileal pouch-anal anastomosis after restorative proctocolectomy for ulcerative colitis. Clin Gastroenterol Hepatol 2006, 4:81-89. [quiz 2-3].
41. Shen B., Sanmiguel C., Bennett A.E., et al. Irritable pouch syndrome is characterized by visceral hypersensitivity. Inflamm Bowel Dis 2010.
42. Lipman J.M., Kiran R.P., Shen B., Remzi F., Fazio V.W. Perioperative factors during ileal pouch-anal anastomosis predict pouchitis. Dis Colon Rectum 2011, 54:311-317.
43. Sandborn W. Pouchitis: risk factors, frequency, natural history, classification and public health perspective. Trends in Inflammatory Bowel Disease 1997, 51-63. Kluwer Academic Publishers, Lancaster, UK.
44. Pardi D.S., D'Haens G., Shen B., Campbell S., Gionchetti P. Clinical guidelines for the management of pouchitis. Inflamm Bowel Dis 2009, 15:1424-1431.
45. Sandborn W.J., Tremaine W.J., Batts K.P., Pemberton J.H., Phillips S.F. Pouchitis after ileal pouch-anal anastomosis: a Pouchitis Disease Activity Index. Mayo Clin Proc 1994, 69:409-415.
46. Evgenikos N., Bartolo D.C., Hamer-Hodges D.W., Ghosh S. Comparison of the Moskowitz criteria and the pouchitis disease activity index (PDAI) for diagnosis of ileoanal pouch inflammation. Colorectal Dis 2001, 3:161-164.
47. Heuschen U.A., Allemeyer E.H., Hinz U., Autschbach F., Uehlein T., Herfarth C., et al. Diagnosing pouchitis: comparative validation of two scoring systems in routine follow-up. Dis Colon Rectum 2002, 45:776-786. [discussion 786-8].
48. Sandborn W., McLeod R., Jewell D. Pharmacotherapy for inducing and maintaining remission in pouchitis. Cochrane Database Syst Rev 2000, CD001176.
49. Madden M.V., McIntyre A.S., Nicholls R.J. Double-blind crossover trial of metronidazole versus placebo in chronic unremitting pouchitis. Dig Dis Sci 1994, 39:1193-1196.
50. Shen B., Achkar J.P., Lashner B.A., Ormsby A.H., Remzi F.H., Brzezinski A., et al. A randomized clinical trial of ciprofloxacin and metronidazole to treat acute pouchitis. Inflamm Bowel Dis 2001, 7:301-305.
51. Holubar S.D., Cima R.R., Sandborn W.J., Pardi D.S. Treatment and prevention of pouchitis after ileal-pouch anal anastomosis for ulcerative colitis. Cochrane Database Syst Rev 2010, 6:CD001176.
52. Shen B., Fazio V.W., Remzi F.H., Bennett A.E., Lopez R., Brzezinski A., et al. Combined ciprofloxacin and tinidazole therapy in the treatment of chronic refractory pouchitis. Dis Colon Rectum 2007, 50:498-508.
53. Gionchetti P., Rizzello F., Venturi A., Ugolini F., Rossi M., Brigidi P., et al. Antibiotic combination therapy in patients with chronic, treatment-resistant pouchitis. Aliment Pharmacol Ther 1999, 13:713-718.
54. Abdelrazeq A.S., Kelly S.M., Lund J.N., Leveson S.H. Rifaximin-ciprofloxacin combination therapy is effective in chronic active refractory pouchitis. Colorectal Dis 2005, 7:182-186.
55. Mimura T., Rizzello F., Helwig U., Poggioli G., Schreiber S., Talbot I.C., et al. Four-week open-label trial of metronidazole and ciprofloxacin for the treatment of recurrent or refractory pouchitis. Aliment Pharmacol Ther 2002, 16:909-917.
56. Gionchetti P., Rizzello F., Poggioli G., Pierangeli F., Laureti S., Morselli C., et al. Oral budesonide in the treatment of chronic refractory pouchitis. Aliment Pharmacol Ther 2007, 25:1231-1236.
57. Navaneethan U., Venkatesh P.G., Bennett A.E., Patel V., Hammel J., Kiran R.P., et al. Impact of budesonide on liver function tests and gut inflammation in patients with primary sclerosing cholangitis and ileal pouch anal anastomosis. J Crohns Colitis 2012, 6:536-542.
58. Sambuelli A., Boerr L., Negreira S., Gil A., Camartino G., Huernos S., et al. Budesonide enema in pouchitis-a double-blind, double-dummy, controlled trial. Aliment Pharmacol Ther 2002, 16:27-34.
59. Winter T.A., Dalton H.R., Merrett M.N., Campbell A., Jewell D.P. Cyclosporin A retention enemas in refractory distal ulcerative colitis and 'pouchitis'. Scand J Gastroenterol 1993, 28:701-704.
60. de Silva H.J., Ireland A., Kettlewell M., Mortensen N., Jewell D.P. Short-chain fatty acid irrigation in severe pouchitis. N Engl J Med 1989, 321:1416-1417.
61. Tremaine W., Sandborn W., Phillips S.F., et al. Short-chain fatty acid (SCFA) enema therapy for treatment-resistant pouchitis following ileal pouch-anal anastomosis (IPAA) for ulcerative colitis. Gastroenterology 1999, 106:A784.
62. Wischmeyer P., Pemberton J.H., Phillips S.F. Chronic pouchitis after ileal pouch-anal anastomosis: responses to butyrate and glutamine suppositories in a pilot study. Mayo Clin Proc 1993, 68:978-981.
63. Ferrante M., D' Haens G., Dewit O., et al. Efficacy of infliximab in refractory pouchitis and Crohn's disease-related complications of the pouch: a Belgian case series. Inflamm Bowel Dis 2010, 16:243-249.
64. Calabrese C., Gionchetti P., Rizzello F., et al. Short-term treatment with infliximab in chronic refractory pouchitis and ileitis. Aliment Pharmacol Ther 2008, 27:759-764.
65. Barreiro-de Acosta M., Garcia-Bosch O., Souto R., Manosa M., Miranda J., Garcia-Sanchez V., et al. Efficacy of infliximab rescue therapy in patients with chronic refractory pouchitis: a multicenter study. Inflamm Bowel Dis 2012, 18:812-817.
66. Barreiro-de Acosta M., Garcia-Bosch O., Gordillo J., Manosa M., Menchen L., Souto R., et al. Efficacy of adalimumab rescue therapy in patients with chronic refractory pouchitis previously treated with infliximab: a case series. Eur J Gastroenterol Hepatol 2012, 24:756-758.
67. Miner P., Wedel M., Bane B., Bradley J. An enema formulation of alicaforsen, an antisense inhibitor of intercellular adhesion molecule-1, in the treatment of chronic, unremitting pouchitis. Aliment Pharmacol Ther 2004, 19:281-286.
68. Gionchetti P., Rizzello F., Venturi A., Brigidi P., Matteuzzi D., Bazzocchi G., et al. Oral bacteriotherapy as maintenance treatment in patients with chronic pouchitis: a double-blind, placebo-controlled trial. Gastroenterology 2000, 119:305-309.
69. Mimura T., Rizzello F., Helwig U., Poggioli G., Schreiber S., Talbot I.C., et al. Once daily high dose probiotic therapy (VSL#3) for maintaining remission in recurrent or refractory pouchitis. Gut 2004, 53:108-114.
70. Gionchetti P., Rizzello F., Helwig U., Venturi A., Lammers K.M., Brigidi P., et al. Prophylaxis of pouchitis onset with probiotic therapy: a double-blind, placebo-controlled trial. Gastroenterology 2003, 124:1202-1209.
71. Kuhbacher T., Ott S.J., Helwig U., Mimura T., Rizzello F., Kleessen B., et al. Bacterial and fungal microbiota in relation to probiotic therapy (VSL#3) in pouchitis. Gut 2006, 55:833-841.
72. Shen B., Fazio V.W., Remzi F.H., Delaney C.P., Bennett A.E., Achkar J.P., et al. Comprehensive evaluation of inflammatory and noninflammatory sequelae of ileal pouch-anal anastomoses. Am J Gastroenterol 2005, 100:93-101.
73. Eaden J.A., Abrams K.R., Mayberry J.F. The risk of colorectal cancer in ulcerative colitis: a meta-analysis. Gut 2001, 48:526-535.
74. Greenstein A.J., Sachar D.B., Smith H., Janowitz H.D., Aufses A.H. A comparison of cancer risk in Crohn's disease and ulcerative colitis. Cancer 1981, 48:2742-2745.
75. Baars J.E., Looman C.W., Steyerberg E.W., Beukers R., Tan A.C., Weusten B.L., et al. The risk of inflammatory bowel disease-related colorectal carcinoma is limited: results from a nationwide nested case-control study. Am J Gastroenterol 2010, 106:319-328.
76. Winther K.V., Jess T., Langholz E., Munkholm P., Binder V. Long-term risk of cancer in ulcerative colitis: a population-based cohort study from Copenhagen County. Clin Gastroenterol Hepatol 2004, 2:1088-1095.
77. Jess T., Loftus E.V., Velayos F.S., Harmsen W.S., Zinsmeister A.R., Smyrk T.C., et al. Risk of intestinal cancer in inflammatory bowel disease: a population-based study from olmsted county, Minnesota. Gastroenterology 2006, 130:1039-1046.
78. Rutter M.D., Saunders B.P., Wilkinson K.H., Rumbles S., Schofield G., Kamm M.A., et al. Thirty-year analysis of a colonoscopic surveillance program for neoplasia in ulcerative colitis. Gastroenterology 2006, 130:1030-1038.
79. Lutgens M.W., Vleggaar F.P., Schipper M.E., Stokkers P.C., van der Woude C.J., Hommes D.W., et al. High frequency of early colorectal cancer in inflammatory bowel disease. Gut 2008, 57:1246-1251.
80. Mathy C., Schneider K., Chen Y.Y., Varma M., Terdiman J.P., Mahadevan U. Gross versus microscopic pancolitis and the occurrence of neoplasia in ulcerative colitis. Inflamm Bowel Dis 2003, 9:351-355.
81. Claessen M.M., Vleggaar F.P., Tytgat K.M., Siersema P.D., van Buuren H.R. High lifetime risk of cancer in primary sclerosing cholangitis. J Hepatol 2009, 50:158-164.
82. Bergeron V., Vienne A., Sokol H., Seksik P., Nion-Larmurier I., Ruskone-Fourmestraux A., et al. Risk factors for neoplasia in inflammatory bowel disease patients with pancolitis. Am J Gastroenterol 2010, [advance online publication, 15 June 2010]. 10.1038/ajg.2010.248.
83. Jayaram H., Satsangi J., Chapman R.W. Increased colorectal neoplasia in chronic ulcerative colitis complicated by primary sclerosing cholangitis: fact or fiction?. Gut 2001, 48:430-434.
84. Rutter M., Saunders B., Wilkinson K., Rumbles S., Schofield G., Kamm M., et al. Severity of inflammation is a risk factor for colorectal neoplasia in ulcerative colitis. Gastroenterology 2004, 126:451-459.
85. Gupta R.B., Harpaz N., Itzkowitz S., Hossain S., Matula S., Kornbluth A., et al. Histologic inflammation is a risk factor for progression to colorectal neoplasia in ulcerative colitis: a cohort study. Gastroenterology 2007, 133:1099-1105. [quiz 1340-1].
86. Jess T., Loftus E.V., Velayos F.S., Winther K.V., Tremaine W.J., Zinsmeister A.R., et al. Risk factors for colorectal neoplasia in inflammatory bowel disease: a nested case-control study from Copenhagen county, Denmark and Olmsted county, Minnesota. Am J Gastroenterol 2007, 102:829-836.
87. Velayos F.S., Loftus E.V., Jess T., Harmsen W.S., Bida J., Zinsmeister A.R., et al. Predictive and protective factors associated with colorectal cancer in ulcerative colitis: a case-control study. Gastroenterology 2006, 130:1941-1949.
88. Gyde S.N., Prior P., Allan R.N., Stevens A., Jewell D.P., Truelove S.C., et al. Colorectal cancer in ulcerative colitis: a cohort study of primary referrals from three centres. Gut 1988, 29:206-217.
89. Nuako K.W., Ahlquist D.A., Mahoney D.W., Schaid D.J., Siems D.M., Lindor N.M. Familial predisposition for colorectal cancer in chronic ulcerative colitis: a case-control study. Gastroenterology 1998, 115:1079-1083.
90. Jonsson B., Ahsgren L., Andersson L.O., Stenling R., Rutegard J. Colorectal cancer surveillance in patients with ulcerative colitis. Br J Surg 1994, 81:689-691.
91. Nugent F.W., Haggitt R.C., Gilpin P.A. Cancer surveillance in ulcerative colitis. Gastroenterology 1991, 100:1241-1248.
92. Lofberg R., Brostrom O., Karlen P., Tribukait B., Ost A. Colonoscopic surveillance in long-standing total ulcerative colitis-a 15-year follow-up study. Gastroenterology 1990, 99:1021-1031.
93. Eaden J., Abrams K., Ekbom A., Jackson E., Mayberry J. Colorectal cancer prevention in ulcerative colitis: a case-control study. Aliment Pharmacol Ther 2000, 14:145-153.
94. Rosenstock E., Farmer R.G., Petras R., Sivak M.V., Rankin G.B., Sullivan B.H. Surveillance for colonic carcinoma in ulcerative colitis. Gastroenterology 1985, 89:1342-1346.
95. Giardiello F.M.G.A., Baylewss T.M., Goodman S.N., Yardley J.H. Colorectal cancer in ulcerative colitis: survival in patients with and without colorectal cancer symptoms. Inflamm Bowel Dis 1996, 2:6-10.
96. Karlen P., Kornfeld D., Brostrom O., Lofberg R., Persson P.G., Ekbom A. Is colonoscopic surveillance reducing colorectal cancer mortality in ulcerative colitis? A population based case control study. Gut 1998, 42:711-714.
97. Lashner B.A., Turner B.C., Bostwick D.G., Frank P.H., Hanauer S.B. Dysplasia and cancer complicating strictures in ulcerative colitis. Dig Dis Sci 1990, 35:349-352.
98. Choi P.M., Nugent F.W., Schoetz D.J., Silverman M.L., Haggitt R.C. Colonoscopic surveillance reduces mortality from colorectal cancer in ulcerative colitis. Gastroenterology 1993, 105:418-424.
99. Collins P.D., Mpofu C., Watson A.J., Rhodes J.M. Strategies for detecting colon cancer and/or dysplasia in patients with inflammatory bowel disease. Cochrane Database Syst Rev 2006, CD000279.
100. Lutgens M.W., Oldenburg B., Siersema P.D., van Bodegraven A.A., Dijkstra G., Hommes D.W., et al. Colonoscopic surveillance improves survival after colorectal cancer diagnosis in inflammatory bowel disease. Br J Cancer 2009, 101:1671-1675.
101. Lim C.H., Dixon M.F., Vail A., Forman D., Lynch D.A., Axon A.T. Ten year follow up of ulcerative colitis patients with and without low grade dysplasia. Gut 2003, 52:1127-1132.
102. Connell W.R., Lennard-Jones J.E., Williams C.B., Talbot I.C., Price A.B., Wilkinson K.H. Factors affecting the outcome of endoscopic surveillance for cancer in ulcerative colitis. Gastroenterology 1994, 107:934-944.
103. Soetikno R.M., Lin O.S., Heidenreich P.A., Young H.S., Blackstone M.O. Increased risk of colorectal neoplasia in patients with primary sclerosing cholangitis and ulcerative colitis: a meta-analysis. Gastrointest Endosc 2002, 56:48-54.
104. Melville D.M., Jass J.R., Morson B.C., Pollock D.J., Richman P.I., Shepherd N.A., et al. Observer study of the grading of dysplasia in ulcerative colitis: comparison with clinical outcome. Hum Pathol 1989, 20:1008-1014.
105. Claessen M.M., Lutgens M.W., van Buuren H.R., Oldenburg B., Stokkers P.C., van der Woude C.J., et al. More right-sided IBD-associated colorectal cancer in patients with primary sclerosing cholangitis. Inflamm Bowel Dis 2009, 15:1331-1336.
106. Scarpa M., van Koperen P.J., Ubbink D.T., Hommes D.W., Ten Kate F.J.W., Bemelman W.A. Systematic review of dysplasia after restorative proctocolectomy for ulcerative colitis. Br J Surg 2007, 94:534-545.
107. Thomas-Gibson S., Rogers P., Cooper S., Man R., Rutter M.D., Suzuki N., et al. Judgement of the quality of bowel preparation at screening flexible sigmoidoscopy is associated with variability in adenoma detection rates. Endoscopy 2006, 38:456-460.
108. Toruner M., Harewood G.C., Loftus E.V., Sandborn W.J., Tremaine W.J., Faubion W.A., et al. Endoscopic factors in the diagnosis of colorectal dysplasia in chronic inflammatory bowel disease. Inflamm Bowel Dis 2005, 11:428-434.
109. Rubin D.T., Rothe J.A., Hetzel J.T., Cohen R.D., Hanauer S.B. Are dysplasia and colorectal cancer endoscopically visible in patients with ulcerative colitis?. Gastrointest Endosc 2007, 65:998-1004.
110. Rutter M.D., Saunders B.P., Wilkinson K.H., Rumbles S., Schofield G., Kamm M.A., et al. Cancer surveillance in longstanding ulcerative colitis: endoscopic appearances help predict cancer risk. Gut 2004, 53:1813-1816.
111. Rutter M.D., Saunders B.P., Wilkinson K.H., Kamm M.A., Williams C.B., Forbes A. Most dysplasia in ulcerative colitis is visible at colonoscopy. Gastrointest Endosc 2004, 60:334-339.
112. Rubin C.E., Haggitt R.C., Burmer G.C., Brentnall T.A., Stevens A.C., Levine D.S., et al. DNA aneuploidy in colonic biopsies predicts future development of dysplasia in ulcerative colitis. Gastroenterology 1992, 103:1611-1620.
113. Awais D., Siegel C.A., Higgins P.D. Modelling dysplasia detection in ulcerative colitis: clinical implications of surveillance intensity. Gut 2009, 58:1498-1503.
114. Kaltz B., Bokemeyer B., Hoffmann J., Porschen R., Rogler G., Schmiegel W. Surveillance colonoscopy in ulcerative colitis patients in Germany. Z Gastroenterol 2007, 45:325-331.
115. Kottachchi D., Yung D., Marshall J.K. Adherence to guidelines for surveillance colonoscopy in patients with ulcerative colitis at a Canadian quaternary care hospital. Can J Gastroenterol 2009, 23:613-617.
116. van Rijn A.F., Fockens P., Siersema P.D., Oldenburg B. Adherence to surveillance guidelines for dysplasia and colorectal carcinoma in ulcerative and Crohn's colitis patients in the Netherlands. World J Gastroenterol 2009, 15:226-230.
117. Velayos F.S., Liu L., Lewis J.D., Allison J.E., Flowers N., Hutfless S., et al. Prevalence of colorectal cancer surveillance for ulcerative colitis in an integrated health care delivery system. Gastroenterology 2010, 139:1511-1518.
118. Kiesslich R., Fritsch J., Holtmann M., Koehler H.H., Stolte M., Kanzler S., et al. Methylene blue-aided chromoendoscopy for the detection of intraepithelial neoplasia and colon cancer in ulcerative colitis. Gastroenterology 2003, 124:880-888.
119. Rutter M.D., Saunders B.P., Schofield G., Forbes A., Price A.B., Talbot I.C. Pancolonic indigo carmine dye spraying for the detection of dysplasia in ulcerative colitis. Gut 2004, 53:256-260.
120. Dekker E., van den Broek F.J., Reitsma J.B., Hardwick J.C., Offerhaus G.J., van Deventer S.J., et al. Narrow-band imaging compared with conventional colonoscopy for the detection of dysplasia in patients with longstanding ulcerative colitis. Endoscopy 2007, 39:216-221.
121. Hurlstone D.P., Sanders D.S., Lobo A.J., McAlindon M.E., Cross S.S. Indigo carmine-assisted high-magnification chromoscopic colonoscopy for the detection and characterisation of intraepithelial neoplasia in ulcerative colitis: a prospective evaluation. Endoscopy 2005, 37:1186-1192.
122. Lashner B.A., Provencher K.S., Seidner D.L., Knesebeck A., Brzezinski A. The effect of folic acid supplementation on the risk for cancer or dysplasia in ulcerative colitis. Gastroenterology 1997, 112:29-32.
123. Lindberg B.U., Broome U., Persson B. Proximal colorectal dysplasia or cancer in ulcerative colitis. The impact of primary sclerosing cholangitis and sulfasalazine: results from a 20-year surveillance study. Dis Colon Rectum 2001, 44:77-85.
124. Moody G.A., Jayanthi V., Probert C.S., Mac Kay H., Mayberry J.F. Long-term therapy with sulphasalazine protects against colorectal cancer in ulcerative colitis: a retrospective study of colorectal cancer risk and compliance with treatment in Leicestershire. Eur J Gastroenterol Hepatol 1996, 8:1179-1183.
125. Pinczowski D., Ekbom A., Baron J., Yuen J., Adami H.O. Risk factors for colorectal cancer in patients with ulcerative colitis: a case-control study. Gastroenterology 1994, 107:117-120.
126. Bernstein C.N., Blanchard J.F., Metge C., Yogendran M. Does the use of 5-aminosalicylates in inflammatory bowel disease prevent the development of colorectal cancer?. Am J Gastroenterol 2003, 98:2784-2788.
127. Rubin D.T., LoSavio A., Yadron N., Huo D., Hanauer S.B. Aminosalicylate therapy in the prevention of dysplasia and colorectal cancer in ulcerative colitis. Clin Gastroenterol Hepatol 2006, 4:1346-1350.
128. van Staa T.P., Card T., Logan R.F., Leufkens H.G. 5-Aminosalicylate use and colorectal cancer risk in inflammatory bowel disease: a large epidemiological study. Gut 2005, 54:1573-1578.
129. Terdiman J.P., Steinbuch M., Blumentals W.A., Ullman T.A., Rubin D.T. 5-Aminosalicylic acid therapy and the risk of colorectal cancer among patients with inflammatory bowel disease. Inflamm Bowel Dis 2007, 13:367-371.
130. Bernstein C.N., Nugent Z., Blanchard J.F. 5-Aminosalicylate is not chemoprophylactic for colorectal cancer in IBD: a population based study. Am J Gastroenterol 2011, 106:731-736.
131. Biancone L., Michetti P., Travis S.P., Escher J., Moser G., Forbes A., et al. ECCO f. European evidence based consensus on the management of ulcerative colitis: special situations. J Crohns Colitis 2008, 2:63-92.
132. Farraye F.A., Odze R.D., Eaden J., Itzkowitz S.H., McCabe R.P., Dassopoulos T., et al. AGA medical position statement on the diagnosis and management of colorectal neoplasia in inflammatory bowel disease. Gastroenterology 2010, 138:738-745.
133. Cairns S.R., Scholefield J.H., Steele R.J., Dunlop M.G., Thomas H.J., Evans G.D., et al. Guidelines for colorectal cancer screening and surveillance in moderate and high risk groups (update from 2002). Gut 2010, 59:666-689.
134. Farraye F.A., Odze R.D., Eaden J., Itzkowitz S.H. AGA technical review on the diagnosis and management of colorectal neoplasia in inflammatory bowel disease. Gastroenterology 2010, 138:746-774. [774 e1-4; quiz e12-3].
135. Beaugerie L., Seksik P., Bouvier A.M., Carbonnel F., Colombel J.F., Faivre J., et al. Thiopurine therapy is associated with a three-fold decrease in the incidence of advanced colorectal neoplasia in IBD patients with longstanding extensive colitis: results from the CESAME cohort. Gastroenterology 2009, 136:A-54.
136. Itzkowitz S.H., Harpaz N. Diagnosis and management of dysplasia in patients with inflammatory bowel diseases. Gastroenterology 2004, 126:1634-1648.
137. Lyakhovich A., Gasche C. Systematic review: molecular chemoprevention of colorectal malignancy by mesalazine. Aliment Pharmacol Ther 2010, 31:202-209.
138. Ullman T., Croog V., Harpaz N., Hossain S., Kornbluth A., Bodian C., et al. Progression to colorectal neoplasia in ulcerative colitis: effect of mesalamine. Clin Gastroenterol Hepatol 2008, 6:1225-1230. [quiz 1177].
139. Tung B.Y., Emond M.J., Haggitt R.C., Bronner M.P., Kimmey M.B., Kowdley K.V., et al. Ursodiol use is associated with lower prevalence of colonic neoplasia in patients with ulcerative colitis and primary sclerosing cholangitis. Ann Intern Med 2001, 134:89-95.
140. Matula S., Croog V., Itzkowitz S., Harpaz N., Bodian C., Hossain S., et al. Chemoprevention of colorectal neoplasia in ulcerative colitis: the effect of 6-mercaptopurine. Clin Gastroenterol Hepatol 2005, 3:1015-1021.
141. Bergeron V., Nion-Larmurier I., Vienne A., Seksik P., Ruskone-Fourmestraux A., Florent C., et al. Azathioprine (AZA) is associated with less histological inflammation of the colon in inactive IBD. Gastroenterology 2010, 138:S-693.
142. Beaugerie L., Brousse N., Bouvier A.M., Colombel J.F., Lemann M., Cosnes J., et al. Lymphoproliferative disorders in patients receiving thiopurines for inflammatory bowel disease: a prospective observational cohort study. Lancet 2009, 374:1617-1625.
143. Pardi D.S., Loftus E.V., Kremers W.K., Keach J., Lindor K.D. Ursodeoxycholic acid as a chemopreventive agent in patients with ulcerative colitis and primary sclerosing cholangitis. Gastroenterology 2003, 124:889-893.
144. Odze R.D. Adenomas and adenoma-like DALMs in chronic ulcerative colitis: a clinical, pathological, and molecular review. Am J Gastroenterol 1999, 94:1746-1750.
145. Riddell R.H., Goldman H., Ransohoff D.F., Appelman H.D., Fenoglio C.M., Haggitt R.C., et al. Dysplasia in inflammatory bowel disease: standardized classification with provisional clinical applications. Hum Pathol 1983, 14:931-968.
146. Goldman H. Significance and detection of dysplasia in chronic colitis. Cancer 1996, 78:2261-2263.
147. Odze R.D., Goldblum J., Noffsinger A., Alsaigh N., Rybicki L.A., Fogt F. Interobserver variability in the diagnosis of ulcerative colitis-associated dysplasia by telepathology. Mod Pathol 2002, 15:379-386.
148. Eaden J., Abrams K., McKay H., Denley H., Mayberry J. Inter-observer variation between general and specialist gastrointestinal pathologists when grading dysplasia in ulcerative colitis. J Pathol 2001, 194:152-157.
149. Blackstone M.O., Riddell R.H., Rogers B.H., Levin B. Dysplasia-associated lesion or mass (DALM) detected by colonoscopy in long-standing ulcerative colitis: an indication for colectomy. Gastroenterology 1981, 80:366-374.
150. Lennard-Jones J.E., Melville D.M., Morson B.C., Ritchie J.K., Williams C.B. Precancer and cancer in extensive ulcerative colitis: findings among 401 patients over 22 years. Gut 1990, 31:800-806.
151. Butt J.H., Konishi F., Morson B.C., Lennard-Jones J.E., Ritchie J.K. Macroscopic lesions in dysplasia and carcinoma complicating ulcerative colitis. Dig Dis Sci 1983, 28:18-26.
152. Vieth M., Behrens H., Stolte M. Sporadic adenoma in ulcerative colitis: endoscopic resection is an adequate treatment. Gut 2006, 55:1151-1155.
153. Torres C., Antonioli D., Odze R.D. Polypoid dysplasia and adenomas in inflammatory bowel disease: a clinical, pathologic, and follow-up study of 89 polyps from 59 patients. Am J Surg Pathol 1998, 22:275-284.
154. Suzuki K., Muto T., Shinozaki M., Yokoyama T., Matsuda K., Masaki T. Differential diagnosis of dysplasia-associated lesion or mass and coincidental adenoma in ulcerative colitis. Dis Colon Rectum 1998, 41:322-327.
155. Odze R.D., Farraye F.A., Hecht J.L., Hornick J.L. Long-term follow-up after polypectomy treatment for adenoma-like dysplastic lesions in ulcerative colitis. Clin Gastroenterol Hepatol 2004, 2:534-541.
156. Rubin P.H., Friedman S., Harpaz N., Goldstein E., Weiser J., Schiller J., et al. Colonoscopic polypectomy in chronic colitis: conservative management after endoscopic resection of dysplastic polyps. Gastroenterology 1999, 117:1295-1300.
157. Friedman S., Odze R.D., Farraye F.A. Management of neoplastic polyps in inflammatory bowel disease. Inflamm Bowel Dis 2003, 9:260-266.
158. Hurlstone D.P., Sanders D.S., Atkinson R., Hunter M.D., McAlindon M.E., Lobo A.J., et al. Endoscopic mucosal resection for flat neoplasia in chronic ulcerative colitis: can we change the endoscopic management paradigm?. Gut 2007, 56:838-846.
159. Engelsgjerd M., Farraye F.A., Odze R.D. Polypectomy may be adequate treatment for adenoma-like dysplastic lesions in chronic ulcerative colitis. Gastroenterology 1999, 117:1288-1294. [discussion 1488-91].
160. Bernstein C.N., Shanahan F., Weinstein W.M. Are we telling patients the truth about surveillance colonoscopy in ulcerative colitis?. Lancet 1994, 343:71-74.
161. Hata K., Watanabe T., Kazama S., Suzuki K., Shinozaki M., Yokoyama T., et al. Earlier surveillance colonoscopy programme improves survival in patients with ulcerative colitis associated colorectal cancer: results of a 23-year surveillance programme in the Japanese population. Br J Cancer 2003, 89:1232-1236.
162. Ullman T., Croog V., Harpaz N., Sachar D., Itzkowitz S. Progression of flat low-grade dysplasia to advanced neoplasia in patients with ulcerative colitis. Gastroenterology 2003, 125:1311-1319.
163. Thomas T., Abrams K.A., Robinson R.J., Mayberry J.F. Meta-analysis: cancer risk of low-grade dysplasia in chronic ulcerative colitis. Aliment Pharmacol Ther 2007, 25:657-668.
164. Ullman T.A., Loftus E.V., Kakar S., Burgart L.J., Sandborn W.J., Tremaine W.J. The fate of low grade dysplasia in ulcerative colitis. Am J Gastroenterol 2002, 97:922-927.
165. Befrits R., Ljung T., Jaramillo E., Rubio C. Low-grade dysplasia in extensive, long-standing inflammatory bowel disease: a follow-up study. Dis Colon Rectum 2002, 45:615-620.
166. Graff L.A., Walker J.R., Bernstein C.N. Depression and anxiety in inflammatory bowel disease: a review of comorbidity and management. Inflamm Bowel Dis 2009, 15:1105-1118.
167. Camara R.J., Ziegler R., Begre S., Schoepfer A.M., von Kanel R. The role of psychological stress in inflammatory bowel disease: quality assessment of methods of 18 prospective studies and suggestions for future research. Digestion 2009, 80:129-139.
168. Rampton D. Does stress influence inflammatory bowel disease? The clinical data. Dig Dis 2009, 27(Suppl. 1):76-79.
169. Maunder R.G., Levenstein S. The role of stress in the development and clinical course of inflammatory bowel disease: epidemiological evidence. Curr Mol Med 2008, 8:247-252.
170. Drossman D.A. Presidential address: gastrointestinal illness and the biopsychosocial model. Psychosom Med 1998, 60:258-267.
171. Engel G.L. The need for a new medical model: a challenge for biomedicine. Science 1977, 196:129-136.
172. Kurina L.M., Goldacre M.J., Yeates D., Gill L.E. Depression and anxiety in people with inflammatory bowel disease. J Epidemiol Community Health 2001, 55:716-720.
173. Bernstein C.N., Singh S., Graff L.A., Walker J.R., Miller N., Cheang M. A prospective population-based study of triggers of symptomatic flares in IBD. Am J Gastroenterol 2010, 105:1994-2002.
174. Mittermaier C., Dejaco C., Waldhoer T., Oefferlbauer-Ernst A., Miehsler W., Beier M., et al. Impact of depressive mood on relapse in patients with inflammatory bowel disease: a prospective 18-month follow-up study. Psychosom Med 2004, 66:79-84.
175. Vidal A., Gomez-Gil E., Sans M., Portella M.J., Salamero M., Pique J.M., et al. Life events and inflammatory bowel disease relapse: a prospective study of patients enrolled in remission. Am J Gastroenterol 2006, 101:775-781.
176. Mikocka-Walus A.A., Turnbull D.A., Moulding N.T., Wilson I.G., Andrews J.M., Holtmann G.J. Controversies surrounding the comorbidity of depression and anxiety in inflammatory bowel disease patients: a literature review. Inflamm Bowel Dis 2007, 13:225-234.
177. Janke K.-H., Klump B., Gregor M., Meisner C., Haeuser W. Determinants of life satisfaction in inflammatory bowel disease. Inflamm Bowel Dis 2005, 11:272-286.
178. Boye B., Jahnsen J., Mokleby K., Leganger S., Jantschek G., Jantschek I., et al. The INSPIRE study: are different personality traits related to disease-specific quality of life (IBDQ) in distressed patients with ulcerative colitis and Crohn's disease?. Inflamm Bowel Dis 2008, 14:680-686.
179. Nahon S., Lahmek P., Saas C., Durance C., Olympie A., Lesgourgues B., et al. Socioeconomic and psychological factors associated with nonadherence to treatment in inflammatory bowel disease patients: results of the ISSEO survey. Inflamm Bowel Dis 2010.
180. Häuser W., Janke K.-H., Klump B., Hinz A. Anxiety and depression in patients with inflammatory bowel disease: comparisons with chronic liver disease patients and the general population. Inflamm Bowel Dis 2011, 17:621-632.
181. Fuller-Thomson E., Sulman J. Depression and inflammatory bowel disease: findings from two nationally representative Canadian surveys. Inflamm Bowel Dis 2006, 12:697-707.
182. Hardt J., Muche-Borowski C., Conrad S., Balzer K., Bokemeyer B., Raspe H. Inflammatory bowel diseases as multi-focal disorders: results from a multi-regional survey on bodily and psychosocial problems in IBD patients. Z Gastroenterol 2010, 48:381-391.
183. Simren M., Axelsson J., Gillberg R., Abrahamsson H., Svedlund J., Bjornsson E.S. Quality of life in inflammatory bowel disease in remission: the impact of IBS-like symptoms and associated psychological factors. Am J Gastroenterol 2002, 97:389-396.
184. Pace F., Molteni P., Bollani S., Sarzi-Puttini P., Stockbrugger R., Bianchi Porro G., et al. Inflammatory bowel disease versus irritable bowel syndrome: a hospital-based, case-control study of disease impact on quality of life. Scand J Gastroenterol 2003, 38:1031-1038.
185. Jones M.P., Wessinger S., Crowell M.D. Coping strategies and interpersonal support in patients with irritable bowel syndrome and inflammatory bowel disease. Clin Gastroenterol Hepatol 2006, 4:474-481.
186. Drossman D.A., Leserman J., Mitchell C.M., Li Z.M., Zagami E.A., Patrick D.L. Health status and health care use in persons with inflammatory bowel disease. A national sample. Dig Dis Sci 1991, 36:1746-1755.
187. Sewitch M.J., Abrahamowicz M., Bitton A., Daly D., Wild G.E., Cohen A., et al. Psychosocial correlates of patient-physician discordance in inflammatory bowel disease. Am J Gastroenterol 2002, 97:2174-2183.
188. von Wietersheim J., Jantschek G., Sommer W., Zawarehi H. Education of patients with inflammatory bowel diseases. Wien Med Wochenschr 1999, 149:352-354.
189. Moser G., Tillinger W., Sachs G., Genser D., Maier-Dobersberger T., Spiess K., et al. Disease-related worries and concerns: a study on out-patients with inflammatory bowel disease. Eur J Gastroenterol Hepatol 1995, 7:853-858.
190. Cima R.R., Anderson K.J., Larson D.W., Dozois E.J., Hassan I., Sandborn W.J., et al. Internet use by patients in an inflammatory bowel disease specialty clinic. Inflamm Bowel Dis 2007, 13:1266-1270.
191. Angelucci E., Orlando A., Ardizzone S., Guidi L., Sorrentino D., Fries W., et al. Internet use among inflammatory bowel disease patients: an Italian multicenter survey. Eur J Gastroenterol Hepatol 2009, 21:1036-1041.
192. Elkjaer M., Burisch J., Avnstrøm S., Lynge E., Munkholm P. Development of a Web-based concept for patients with ulcerative colitis and 5-aminosalicylic acid treatment. Eur J Gastroenterol Hepatol 2010, 22:695-704.
193. de Boer A.G., Sprangers M.A., Bartelsman J.F., de Haes H.C. Predictors of health care utilization in patients with inflammatory bowel disease: a longitudinal study. Eur J Gastroenterol Hepatol 1998, 10:783-789.
194. Lakatos P.L. Prevalence, predictors, and clinical consequences of medical adherence in IBD: how to improve it?. World J Gastroenterol 2009, 15:4234-4239.
195. Kennedy A.P., Nelson E., Reeves D., Richardson G., Roberts C., Robinson A., et al. A randomised controlled trial to assess the effectiveness and cost of a patient orientated self management approach to chronic inflammatory bowel disease. Gut 2004, 53:1639-1645.
196. Robinson A., Thompson D.G., Wilkin D., Roberts C. Guided self-management and patient-directed follow-up of ulcerative colitis: a randomised trial. Lancet 2001, 358:976-981.
197. Borgaonkar M.R., Townson G., Donnelly M., Irvine E.J. Providing disease-related information worsens health-related quality of life in inflammatory bowel disease. Inflamm Bowel Dis 2002, 8:264-269.
198. Lange A., Haslbeck E., Andus T., et al. Patient education in inflammatory bowel disease. Z Gastroenterol 1996, 34:411-415.
199. Larsson K., Sundberg Hjelm M., Karlbom U., Nordin K., Anderberg U.M., Loof L. A group-based patient education programme for high-anxiety patients with Crohn disease or ulcerative colitis. Scand J Gastroenterol 2003, 38:763-769.
200. Bregenzer N., Lange A., Furst A., Gross V., Scholmerich J., Andus T. Patient education in inflammatory bowel disease does not influence patients knowledge and long-term psychosocial well-being. Z Gastroenterol 2005, 43:367-371.
201. Oxelmark L., Magnusson A., Löfberg R., Hillerås P. Group-based intervention program in inflammatory bowel disease patients: effects on quality of life. Inflamm Bowel Dis 2007, 13:182-190.
202. Jaghult S., Larson J., Wredling R., Kapraali M. A multiprofessional education programme for patients with inflammatory bowel disease: a randomized controlled trial. Scand J Gastroenterol 2007, 42:1452-1459.
203. Miehsler W., Weichselberger M., Offerlbauer-Ernst A., Dejaco C., Reinisch W., Vogelsang H., et al. Assessing the demand for psychological care in chronic diseases: development and validation of a questionnaire based on the example of inflammatory bowel disease. Inflamm Bowel Dis 2004, 10:637-645.
204. Miehsler W., Dejaco C., Moser G. Factor analysis of ADAPT questionnaire for assessment of subjective need for psychological interventions. Inflamm Bowel Dis 2008, 14:142-143.
205. Guthrie E., Jackson J., Shaffer J., Thompson D., Tomenson B., Creed F. Psychological disorder and severity of inflammatory bowel disease predict health-related quality of life in ulcerative colitis and Crohn's disease. Am J Gastroenterol 2002, 97:1994-1999.
206. Irvine E.J. Quality of life-measurement in inflammatory bowel disease. Scand J Gastroenterol Suppl 1993, 199:36-39.
207. Drossman D.A., Leserman J., Li Z.M., Mitchell C.M., Zagami E.A., Patrick D.L. The rating form of IBD patient concerns: a new measure of health status. Psychosom Med 1991, 53:701-712.
208. Sewitch M.J., Abrahamowicz M., Bitton A., Daly D., Wild G.E., Cohen A., et al. Psychological distress, social support, and disease activity in patients with inflammatory bowel disease. Am J Gastroenterol 2001, 96:1470-1479.
209. Wahed M., Corser M., Goodhand J.R., Rampton D.S. Does psychological counseling alter the natural history of inflammatory bowel disease?. Inflamm Bowel Dis 2010, 16:664-669.
210. Casellas F., Fontanet G., Borruel N., Malagelada J.R. The opinion of patients with inflammatory bowel disease on healthcare received. Rev Esp Enferm Dig 2004, 96:174-184.
211. Patterson M. An evaluation of the effectiveness of psychotherapy in the treatment of ulcerative colitis. Gastroenterology 1964, 71:286.
212. Mussell M., Böcker U., Nagel N., Olbrich R., Singer M.V. Reducing psychological distress in patients with inflammatory bowel disease by cognitive-behavioural treatment: exploratory study of effectiveness. Scand J Gastroenterol 2003, 38:755-762.
213. Schwarz S.P., Blanchard E.B. Evaluation of a psychological treatment for inflammatory bowel disease. Behav Res Ther 1991, 29:167-177.
214. Milne B., Joachim G., Niedhardt J. A stress management program for inflammatory bowel disease. J Adv Nurs 1986, 11:561-567.
215. Elsenbruch S., Langhorst J., Popkirowa K., Müller T., Luedtke R., Franken U., et al. Effects of mind-body therapy on quality of life and neuroendocrine and cellular immune functions in patients with ulcerative colitis. Psychother Psychosom 2005, 74:277-287.
216. Langhorst J., Mueller T., Luedtke R., Franken U., Paul A., Michalsen A., et al. Effects of a comprehensive lifestyle modification program on quality-of-life in patients with ulcerative colitis: a twelve-month follow-up. Scand J Gastroenterol 2007, 42:734-745.
217. Shaw L., Ehrlich A. Relaxation training as a treatment for chronic pain caused by ulcerative colitis. Pain 1987, 29:287-293.
218. Timmer A., Preiss J.C., Motschall E., Rücker G., Jantschek G., Moser G. Psychological interventions for treatment of inflammatory bowel disease. Cochrane Database Syst Rev 2011, CD006913-CD006913.
219. Mikocka-Walus A.A., Turnbull D.A., Moulding N.T., Wilson I.G., Andrews J.M., Holtmann G.J. Antidepressants and inflammatory bowel disease: a systematic review. Clin Pract Epidemiol Ment Health 2006, 2:24.
220. Danese S., Semeraro S., Papa A., Roberto I., Scaldaferri F., Fedeli G., et al. Extraintestinal manifestations in inflammatory bowel disease. World J Gastroenterol 2005, 11:7227-7236.
221. Barreiro-de Acosta M., Dominguez-Munoz J.E., Nunez-Pardo de Vera M.C., Lozano-Leon A., Lorenzo A., Pena S. Relationship between clinical features of Crohn's disease and the risk of developing extraintestinal manifestations. Eur J Gastroenterol Hepatol 2007, 19:73-78.
222. Orchard T.R., Wordsworth B.P., Jewell D.P. Peripheral arthropathies in inflammatory bowel disease: their articular distribution and natural history. Gut 1998, 42:387-391.
223. Fornaciari G., Salvarani C., Beltrami M., Macchioni P., Stockbrugger R.W., Russel M.G. Muscoloskeletal manifestations in inflammatory bowel disease. Can J Gastroenterol 2001, 15:399-403.
224. de Vlam K., Mielants H., Cuvelier C., De Keyser F., Veys E.M., De Vos M. Spondyloarthropathy is underestimated in inflammatory bowel disease: prevalence and HLA association. J Rheumatol 2000, 27:2860-2865.
225. Peeters H., Vander Cruyssen B., Mielants H., de Vlam K., Vermeire S., Louis E., et al. Clinical and genetic factors associated with sacroiliitis in Crohn's disease. J Gastroenterol Hepatol 2008, 23:132-137.
226. Queiro R., Maiz O., Intxausti J., de Dios J.R., Belzunegui J., Gonzalez C., et al. Subclinical sacroiliitis in inflammatory bowel disease: a clinical and follow-up study. Clin Rheumatol 2000, 19:445-449.
227. van der Linden S., Valkenburg H.A., Cats A. Evaluation of diagnostic criteria for ankylosing spondylitis. A proposal for modification of the New York criteria. Arthritis Rheum 1984, 27:361-368.
228. Braun J., Baraliakos X., Golder W., Hermann K.G., Listing J., Brandt J., et al. Analysing chronic spinal changes in ankylosing spondylitis: a systematic comparison of conventional x rays with magnetic resonance imaging using established and new scoring systems. Ann Rheum Dis 2004, 63:1046-1055.
229. Puhakka K.B., Jurik A.G., Schiottz-Christensen B., Hansen G.V., Egund N., Christiansen J.V., et al. MRI abnormalities of sacroiliac joints in early spondylarthropathy: a 1-year follow-up study. Scand J Rheumatol 2004, 33:332-338.
230. Steer S., Jones H., Hibbert J., Kondeatis E., Vaughan R., Sanderson J., et al. Low back pain, sacroiliitis, and the relationship with HLA-B27 in Crohn's disease. J Rheumatol 2003, 30:518-522.
231. Ferraz M.B., Tugwell P., Goldsmith C.H., Atra E. Meta-analysis of sulfasalazine in ankylosing spondylitis. J Rheumatol 1990, 17:1482-1486.
232. Palm O., Moum B., Ongre A., Gran J.T. Prevalence of ankylosing spondylitis and other spondyloarthropathies among patients with inflammatory bowel disease: a population study (the IBSEN study). J Rheumatol 2002, 29:511-515.
233. Herfarth H., Obermeier F., Andus T., Rogler G., Nikolaus S., Kuehbacher T., et al. Improvement of arthritis and arthralgia after treatment with infliximab (Remicade) in a German prospective, open-label, multicenter trial in refractory Crohn's disease. Am J Gastroenterol 2002, 97:2688-2690.
234. Van den Bosch F., Kruithof E., De Vos M., De Keyser F., Mielants H. Crohn's disease associated with spondyloarthropathy: effect of TNF-alpha blockade with infliximab on articular symptoms. Lancet 2000, 356:1821-1822.
235. Generini S., Giacomelli R., Fedi R., Fulminis A., Pignone A., Frieri G., et al. Infliximab in spondyloarthropathy associated with Crohn's disease: an open study on the efficacy of inducing and maintaining remission of musculoskeletal and gut manifestations. Ann Rheum Dis 2004, 63:1664-1669.
236. Marzo-Ortega H., McGonagle D., O'Connor P., Emery P. Efficacy of etanercept for treatment of Crohn's related spondyloarthritis but not colitis. Ann Rheum Dis 2003, 62:74-76.
237. Cipolla G., Crema F., Sacco S., Moro E., de Ponti F., Frigo G. Nonsteroidal anti-inflammatory drugs and inflammatory bowel disease: current perspectives. Pharmacol Res 2002, 46:1-6.
238. Felder J.B., Korelitz B.I., Rajapakse R., Schwarz S., Horatagis A.P., Gleim G. Effects of nonsteroidal antiinflammatory drugs on inflammatory bowel disease: a case-control study. Am J Gastroenterol 2000, 95:1949-1954.
239. Bonner G.F., Fakhri A., Vennamaneni S.R. A long-term cohort study of nonsteroidal anti-inflammatory drug use and disease activity in outpatients with inflammatory bowel disease. Inflamm Bowel Dis 2004, 10:751-757.
240. El Miedany Y., Youssef S., Ahmed I., El Gaafary M. The gastrointestinal safety and effect on disease activity of etoricoxib, a selective cox-2 inhibitor in inflammatory bowel diseases. Am J Gastroenterol 2006, 101:311-317.
241. Sandborn W.J., Stenson W.F., Brynskov J., Lorenz R.G., Steidle G.M., Robbins J.L., et al. Safety of celecoxib in patients with ulcerative colitis in remission: a randomized, placebo-controlled, pilot study. Clin Gastroenterol Hepatol 2006, 4:203-211.
242. Clegg D.O., Reda D.J., Weisman M.H., Blackburn W.D., Cush J.J., Cannon G.W., et al. Comparison of sulfasalazine and placebo in the treatment of ankylosing spondylitis. A Department of Veterans Affairs Cooperative Study. Arthritis Rheum 1996, 39:2004-2012.
243. Dougados M., vam der Linden S., Leirisalo-Repo M., Huitfeldt B., Juhlin R., Veys E., et al. Sulfasalazine in the treatment of spondylarthropathy. A randomized, multicenter, double-blind, placebo-controlled study. Arthritis Rheum 1995, 38:618-627.
244. Van Den Bosch F., Kruithof E., Baeten D., Herssens A., de Keyser F., Mielants H., et al. Randomized double-blind comparison of chimeric monoclonal antibody to tumor necrosis factor alpha (infliximab) versus placebo in active spondylarthropathy. Arthritis Rheum 2002, 46:755-765.
245. Zochling J., van der Heijde D., Dougados M., Braun J. Current evidence for the management of ankylosing spondylitis: a systematic literature review for the ASAS/EULAR management recommendations in ankylosing spondylitis. Ann Rheum Dis 2006, 65:423-432.
246. Braun J., Baraliakos X., Listing J., Fritz C., Alten R., Burmester G., et al. Persistent clinical efficacy and safety of anti-tumour necrosis factor alpha therapy with infliximab in patients with ankylosing spondylitis over 5years: evidence for different types of response. Ann Rheum Dis 2008, 67:340-345.
247. Braun J., Brandt J., Listing J., Zink A., Alten R., Golder W., et al. Treatment of active ankylosing spondylitis with infliximab: a randomised controlled multicentre trial. Lancet 2002, 359:1187-1193.
248. Gorman J.D., Sack K.E., Davis J.C. Treatment of ankylosing spondylitis by inhibition of tumor necrosis factor alpha. N Engl J Med 2002, 346:1349-1356.
249. Lambert R.G., Salonen D., Rahman P., Inman R.D., Wong R.L., Einstein S.G., et al. Adalimumab significantly reduces both spinal and sacroiliac joint inflammation in patients with ankylosing spondylitis: a multicenter, randomized, double-blind, placebo-controlled study. Arthritis Rheum 2007, 56:4005-4014.
250. van der Heijde D., Dijkmans B., Geusens P., Sieper J., DeWoody K., Williamson P., et al. Efficacy and safety of infliximab in patients with ankylosing spondylitis: results of a randomized, placebo-controlled trial (ASSERT). Arthritis Rheum 2005, 52:582-591.
251. van der Heijde D., Kivitz A., Schiff M.H., Sieper J., Dijkmans B.A., Braun J., et al. Efficacy and safety of adalimumab in patients with ankylosing spondylitis: results of a multicenter, randomized, double-blind, placebo-controlled trial. Arthritis Rheum 2006, 54:2136-2146.
252. Reinshagen M. Osteoporosis in inflammatory bowel disease. J Crohns Colitis 2008, 2:202-207.
253. Wahner H. Technical aspects and clinical interpretation of bone mineral measurements. Public Health Rep 1989, 104(Suppl.):27-30.
254. Klaus J., Armbrecht G., Steinkamp M., Bruckel J., Rieber A., Adler G., et al. High prevalence of osteoporotic vertebral fractures in patients with Crohn's disease. Gut 2002, 51:654-658.
255. Siffledeen J.S., Siminoski K., Jen H., Fedorak R.N. Vertebral fractures and role of low bone mineral density in Crohn's disease. Clin Gastroenterol Hepatol 2007, 5:721-728.
256. Stockbrugger R.W., Schoon E.J., Bollani S., Mills P.R., Israeli E., Landgraf L., et al. Discordance between the degree of osteopenia and the prevalence of spontaneous vertebral fractures in Crohn's disease. Aliment Pharmacol Ther 2002, 16:1519-1527.
257. Black D.M., Steinbuch M., Palermo L., Dargent-Molina P., Lindsay R., Hoseyni M.S., et al. An assessment tool for predicting fracture risk in postmenopausal women. Osteoporos Int 2001, 12:519-528.
258. Goodhand J.R., Kamperidis N., Nguyen H., Wahed M., Rampton D.S. Application of the WHO fracture risk assessment tool (FRAX) to predict need for DEXA scanning and treatment in patients with inflammatory bowel disease at risk of osteoporosis. Aliment Pharmacol Ther 2011, 33:551-558.
259. Bischoff-Ferrari H.A., Willett W.C., Wong J.B., Giovannucci E., Dietrich T., Dawson-Hughes B. Fracture prevention with vitamin D supplementation: a meta-analysis of randomized controlled trials. JAMA 2005, 293:2257-2264.
260. Reffitt D.M., Meenan J., Sanderson J.D., Jugdaohsingh R., Powell J.J., Thompson R.P. Bone density improves with disease remission in patients with inflammatory bowel disease. Eur J Gastroenterol Hepatol 2003, 15:1267-1273.
261. Requena L., Sanchez Yus E. Erythema nodosum. Semin Cutan Med Surg 2007, 26:114-125.
262. Trost L.B., McDonnell J.K. Important cutaneous manifestations of inflammatory bowel disease. Postgrad Med J 2005, 81:580-585.
263. Freeman H.J. Erythema nodosum and pyoderma gangrenosum in 50 patients with Crohn's disease. Can J Gastroenterol 2005, 19:603-606.
264. Nguyen G.C., Torres E.A., Regueiro M., Bromfield G., Bitton A., Stempak J., et al. Inflammatory bowel disease characteristics among African Americans, Hispanics, and non-Hispanic Whites: characterization of a large North American cohort. Am J Gastroenterol 2006, 101:1012-1023.
265. Emanuel P.O., Phelps R.G. Metastatic Crohn's disease: a histopathologic study of 12 cases. J Cutan Pathol 2008, 35:457-461.
266. Orchard T.R., Chua C.N., Ahmad T., Cheng H., Welsh K.I., Jewell D.P. Uveitis and erythema nodosum in inflammatory bowel disease: clinical features and the role of HLA genes. Gastroenterology 2002, 123:714-718.
267. Clayton T.H., Walker B.P., Stables G.I. Treatment of chronic erythema nodosum with infliximab. Clin Exp Dermatol 2006, 31:823-824.
268. Ortego-Centeno N., Callejas-Rubio J.L., Sanchez-Cano D., Caballero-Morales T. Refractory chronic erythema nodosum successfully treated with adalimumab. J Eur Acad Dermatol Venereol 2007, 21:408-410.
269. Callen J.P., Jackson J.M. Pyoderma gangrenosum: an update. Rheum Dis Clin North Am 2007, 33:787-802. [vi].
270. Menachem Y., Gotsman I. Clinical manifestations of pyoderma gangrenosum associated with inflammatory bowel disease. Isr Med Assoc J 2004, 6:88-90.
271. Weenig R.H., Davis M.D., Dahl P.R., Su W.P. Skin ulcers misdiagnosed as pyoderma gangrenosum. N Engl J Med 2002, 347:1412-1418.
272. Brooklyn T., Dunnill G., Probert C. Diagnosis and treatment of pyoderma gangrenosum. BMJ 2006, 333:181-184.
273. Juillerat P., Mottet C., Pittet V., Froehlich F., Felley C., Gonvers J.J., et al. Extraintestinal manifestations of Crohn's disease. Digestion 2007, 76:141-148.
274. Matis W.L., Ellis C.N., Griffiths C.E., Lazarus G.S. Treatment of pyoderma gangrenosum with cyclosporine. Arch Dermatol 1992, 128:1060-1064.
275. Baumgart D.C., Wiedenmann B., Dignass A.U. Rescue therapy with tacrolimus is effective in patients with severe and refractory inflammatory bowel disease. Aliment Pharmacol Ther 2003, 17:1273-1281.
276. Regueiro M., Valentine J., Plevy S., Fleisher M.R., Lichtenstein G.R. Infliximab for treatment of pyoderma gangrenosum associated with inflammatory bowel disease. Am J Gastroenterol 2003, 98:1821-1826.
277. Brooklyn T.N., Dunnill M.G., Shetty A., Bowden J.J., Williams J.D., Griffiths C.E., et al. Infliximab for the treatment of pyoderma gangrenosum: a randomised, double blind, placebo controlled trial. Gut 2006, 55:505-509.
278. Poritz L.S., Lebo M.A., Bobb A.D., Ardell C.M., Koltun W.A. Management of peristomal pyoderma gangrenosum. J Am Coll Surg 2008, 206:311-315.
279. Cohen P.R. Sweet's syndrome-a comprehensive review of an acute febrile neutrophilic dermatosis. Orphanet J Rare Dis 2007, 2:34.
280. Travis S., Innes N., Davies M.G., Daneshmend T., Hughes S. Sweet's syndrome: an unusual cutaneous feature of Crohn's disease or ulcerative colitis. The South West Gastroenterology Group. Eur J Gastroenterol Hepatol 1997, 9:715-720.
281. Ytting H., Vind I., Bang D., Munkholm P. Sweet's syndrome-an extraintestinal manifestation in inflammatory bowel disease. Digestion 2005, 72:195-200.
282. Fiorino G., Allez M., Malesci A., Danese S. Review article: anti TNF-alpha induced psoriasis in patients with inflammatory bowel disease. Aliment Pharmacol Ther 2009, 29:921-927.
283. Rahier J.F., Buche S., Peyrin-Biroulet L., Bouhnik Y., Duclos B., Louis E., et al. Severe skin lesions cause patients with inflammatory bowel disease to discontinue anti-tumor necrosis factor therapy. Clin Gastroenterol Hepatol 2010, 8:1048-1055.
284. Cleynen I., Vermeire S. Paradoxical inflammation induced by anti-TNF agents in patients with IBD. Nat Rev Gastroenterol Hepatol 2012.
285. Collamer A.N., Battafarano D.F. Psoriatic skin lesions induced by tumor necrosis factor antagonist therapy: clinical features and possible immunopathogenesis. Semin Arthritis Rheum 2010, 40:233-240.
286. Collamer A.N., Guerrero K.T., Henning J.S., Battafarano D.F. Psoriatic skin lesions induced by tumor necrosis factor antagonist therapy: a literature review and potential mechanisms of action. Arthritis Rheum 2008, 59:996-1001.
287. Mintz R., Feller E.R., Bahr R.L., Shah S.A. Ocular manifestations of inflammatory bowel disease. Inflamm Bowel Dis 2004, 10:135-139.
288. Mendes F.D., Levy C., Enders F.B., Loftus E.V., Angulo P., Lindor K.D. Abnormal hepatic biochemistries in patients with inflammatory bowel disease. Am J Gastroenterol 2007, 102:344-350.
289. Vitellas K.M., Enns R.A., Keogan M.T., Freed K.S., Spritzer C.E., Baillie J., et al. Comparison of MR cholangiopancreatographic techniques with contrast-enhanced cholangiography in the evaluation of sclerosing cholangitis. AJR Am J Roentgenol 2002, 178:327-334.
290. Talwalkar J.A., Angulo P., Johnson C.D., Petersen B.T., Lindor K.D. Cost-minimization analysis of MRC versus ERCP for the diagnosis of primary sclerosing cholangitis. Hepatology 2004, 40:39-45.
291. Cullen S.N., Chapman R.W. The medical management of primary sclerosing cholangitis. Semin Liver Dis 2006, 26:52-61.
292. Lindor K.D. Ursodiol for primary sclerosing cholangitis. Mayo Primary Sclerosing Cholangitis-Ursodeoxycholic Acid Study Group. N Engl J Med 1997, 336:691-695.
293. Mitchell S.A., Bansi D.S., Hunt N., Von Bergmann K., Fleming K.A., Chapman R.W. A preliminary trial of high-dose ursodeoxycholic acid in primary sclerosing cholangitis. Gastroenterology 2001, 121:900-907.
294. Lindor K.D., Kowdley K.V., Luketic V.A., Harrison M.E., McCashland T., Befeler A.S., et al. High-dose ursodeoxycholic acid for the treatment of primary sclerosing cholangitis. Hepatology 2009, 50:808-814.
295. Sjoqvist U., Tribukait B., Ost A., Einarsson C., Oxelmark L., Lofberg R. Ursodeoxycholic acid treatment in IBD-patients with colorectal dysplasia and/or DNA-aneuploidy: a prospective, double-blind, randomized controlled pilot study. Anticancer Res 2004, 24:3121-3127.
296. Van Thiel D.H., Carroll P., Abu-Elmagd K., Rodriguez-Rilo H., Irish W., McMichael J., et al. Tacrolimus (FK 506), a treatment for primary sclerosing cholangitis: results of an open-label preliminary trial. Am J Gastroenterol 1995, 90:455-459.
297. Graziadei I.W., Wiesner R.H., Batts K.P., Marotta P.J., LaRusso N.F., Porayko M.K., et al. Recurrence of primary sclerosing cholangitis following liver transplantation. Hepatology 1999, 29:1050-1056.
298. Bernstein C.N., Nabalamba A. Hospitalization-based major comorbidity of inflammatory bowel disease in Canada. Can J Gastroenterol 2007, 21:507-511.
299. Miehsler W., Reinisch W., Valic E., Osterode W., Tillinger W., Feichtenschlager T., et al. Is inflammatory bowel disease an independent and disease specific risk factor for thromboembolism?. Gut 2004, 53:542-548.
300. Nguyen G.C., Sam J. Rising prevalence of venous thromboembolism and its impact on mortality among hospitalized inflammatory bowel disease patients. Am J Gastroenterol 2008, 103:2272-2280.
301. Danese S., Papa A., Saibeni S., Repici A., Malesci A., Vecchi M. Inflammation and coagulation in inflammatory bowel disease: the clot thickens. Am J Gastroenterol 2007, 102:174-186.
302. Bernstein C.N., Blanchard J.F., Houston D.S., Wajda A. The incidence of deep venous thrombosis and pulmonary embolism among patients with inflammatory bowel disease: a population-based cohort study. Thromb Haemost 2001, 85:430-434.
303. Kappelman M.D., Horvath-Puho E., Sandler R.S., Rubin D.T., Ullman T.A., Pedersen L., et al. Thromboembolic risk among Danish children and adults with inflammatory bowel diseases: a population-based nationwide study. Gut 2011, 60:937-943.
304. Novacek G., Weltermann A., Sobala A., Tilg H., Petritsch W., Reinisch W., et al. Inflammatory bowel disease is a risk factor for recurrent venous thromboembolism. Gastroenterology 2009, 139:779-787.
305. Guidelines on diagnosis and management of acute pulmonary embolism. Task Force on Pulmonary Embolism, European Society of Cardiology. Eur Heart J 2000, 21:1301-1336.
306. Qaseem A., Snow V., Barry P., Hornbake E.R., Rodnick J.E., Tobolic T., et al. Current diagnosis of venous thromboembolism in primary care: a clinical practice guideline from the American Academy of Family Physicians and the American College of Physicians. Ann Intern Med 2007, 146:454-458.
307. Prevention and treatment of venous thromboembolism. International Consensus Statement (guidelines according to scientific evidence). Int Angiol 2006, 25:101-161.
308. Kearon C., Kahn S.R., Agnelli G., Goldhaber S., Raskob G.E., Comerota A.J. Antithrombotic therapy for venous thromboembolic disease: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 2008, 133:454S-545S.
309. Shen J., Ran Z.H., Tong J.L., Xiao S.D. Meta-analysis: the utility and safety of heparin in the treatment of active ulcerative colitis. Aliment Pharmacol Ther 2007, 26:653-663.
310. Geerts W.H., Bergqvist D., Pineo G.F., Heit J.A., Samama C.M., Lassen M.R., et al. Prevention of venous thromboembolism: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 2008, 133:381S-453S.
311. Dentali F., Douketis J.D., Gianni M., Lim W., Crowther M.A. Meta-analysis: anticoagulant prophylaxis to prevent symptomatic venous thromboembolism in hospitalized medical patients. Ann Intern Med 2007, 146:278-288.
312. Alikhan R., Cohen A.T., Combe S., Samama M.M., Desjardins L., Eldor A., et al. Risk factors for venous thromboembolism in hospitalized patients with acute medical illness: analysis of the MEDENOX Study. Arch Intern Med 2004, 164:963-968.
313. Samama M.M., Cohen A.T., Darmon J.Y., Desjardins L., Eldor A., Janbon C., et al. A comparison of enoxaparin with placebo for the prevention of venous thromboembolism in acutely ill medical patients. Prophylaxis in Medical Patients with Enoxaparin Study Group. N Engl J Med 1999, 341:793-800.
314. Gasche C. Anemia in IBD: the overlooked villain. Inflamm Bowel Dis 2000, 6:142-150. [discussion 151].
315. Voegtlin M, Vavricka SR, Schoepfer AM, Straumann A, Voegtlin J, Rogler G, Ballabeni P, Pittet V, Buser A, Fried M, Beglinger C. Prevalence of anaemia in inflammatory bowel disease in Switzerland: a cross-sectional study in patients from private practices and university hospitals. J Crohns Colitis;4:642-8.
316. Gisbert J.P., Gomollon F. Common misconceptions in the diagnosis and management of anemia in inflammatory bowel disease. Am J Gastroenterol 2008, 103:1299-1307.
317. Bennett-Guerrero E., Veldman T.H., Doctor A., Telen M.J., Ortel T.L., Reid T.S., et al. Evolution of adverse changes in stored RBCs. Proc Natl Acad Sci U S A 2007, 104:17063-17068.
318. Wells C.W., Lewis S., Barton J.R., Corbett S. Effects of changes in hemoglobin level on quality of life and cognitive function in inflammatory bowel disease patients. Inflamm Bowel Dis 2006, 12:123-130.
319. Bruewer M., Utech M., Rijcken E.J., Anthoni C., Laukoetter M.G., Kersting S., et al. Preoperative steroid administration: effect on morbidity among patients undergoing intestinal bowel resection for Crohns disease. World J Surg 2003, 27:1306-1310.
320. Kulnigg S., Gasche C. Systematic review: managing anaemia in Crohn's disease. Aliment Pharmacol Ther 2006, 24:1507-1523.
321. Gasche C., Berstad A., Befrits R., Beglinger C., Dignass A., Erichsen K., et al. Guidelines on the diagnosis and management of iron deficiency and anemia in inflammatory bowel diseases. Inflamm Bowel Dis 2007, 13:1545-1553.
322. Gomollon F., Gisbert J.P. Anemia and inflammatory bowel diseases. World J Gastroenterol 2009, 15:4659-4665.
323. Stein J, Hartmann F, Dignass AU. Diagnosis and management of iron deficiency anemia in patients with IBD. Nat Rev, Gastroenterol Hepatol;7:599-610.
324. Sullivan K.M., Mei Z., Grummer-Strawn L., Parvanta I. Haemoglobin adjustments to define anaemia. Trop Med Int Health 2008, 13:1267-1271.
325. Weiss G., Goodnough L.T. Anemia of chronic disease. N Engl J Med 2005, 352:1011-1023.
326. Bermejo F., Garcia-Lopez S. A guide to diagnosis of iron deficiency and iron deficiency anemia in digestive diseases. World J Gastroenterol 2009, 15:4638-4643.
327. Guagnozzi D., Severi C., Ialongo P., Viscido A., Patrizi F., Testino G., et al. Ferritin as a simple indicator of iron deficiency in anemic IBD patients. Inflamm Bowel Dis 2006, 12:150-151.
328. Munoz M., Villar I., Garcia-Erce J.A. An update on iron physiology. World J Gastroenterol 2009, 15:4617-4626.
329. Thomas C., Thomas L. Biochemical markers and hematologic indices in the diagnosis of functional iron deficiency. Clin Chem 2002, 48:1066-1076.
330. Kulnigg S., Teischinger L., Dejaco C., Waldhor T., Gasche C. Rapid recurrence of IBD-associated anemia and iron deficiency after intravenous iron sucrose and erythropoietin treatment. Am J Gastroenterol 2009, 104:1460-1467.
331. Goddard A.F., McIntyre A.S., Scott B.B. Guidelines for the management of iron deficiency anaemia. British Society of Gastroenterology. Gut 2000, 46(Suppl. 3-4):IV1-IV5.
332. Ganzoni A.M. Intravenous iron-dextran: therapeutic and experimental possibilities. Schweiz Med Wochenschr 1970, 100:301-303.
333. Kulnigg S., Stoinov S., Simanenkov V., Dudar L.V., Karnafel W., Garcia L.C., et al. A novel intravenous iron formulation for treatment of anemia in inflammatory bowel disease: the ferric carboxymaltose (FERINJECT) randomized controlled trial. Am J Gastroenterol 2008, 103:1182-1192.
334. Auerbach M., Coyne D., Ballard H. Intravenous iron: from anathema to standard of care. Am J Hematol 2008, 83:580-588.
335. Gisbert J.P., Bermejo F., Pajares R., Perez-Calle J.L., Rodriguez M., Algaba A., et al. Oral and intravenous iron treatment in inflammatory bowel disease: hematological response and quality of life improvement. Inflamm Bowel Dis 2009, 15:1485-1491.
336. Aghdassi E., Carrier J., Cullen J., Tischler M., Allard J.P. Effect of iron supplementation on oxidative stress and intestinal inflammation in rats with acute colitis. Dig Dis Sci 2001, 46:1088-1094.
337. Carrier J., Aghdassi E., Cullen J., Allard J.P. Iron supplementation increases disease activity and vitamin E ameliorates the effect in rats with dextran sulfate sodium-induced colitis. J Nutr 2002, 132:3146-3150.
338. Carrier J., Aghdassi E., Platt I., Cullen J., Allard J.P. Effect of oral iron supplementation on oxidative stress and colonic inflammation in rats with induced colitis. Aliment Pharmacol Ther 2001, 15:1989-1999.
339. Erichsen K., Ulvik R.J., Nysaeter G., Johansen J., Ostborg J., Berstad A., et al. Oral ferrous fumarate or intravenous iron sucrose for patients with inflammatory bowel disease. Scand J Gastroenterol 2005, 40:1058-1065.
340. Chertow G.M., Mason P.D., Vaage-Nilsen O., Ahlmen J. Update on adverse drug events associated with parenteral iron. Nephrol Dial Transplant 2006, 21:378-382.
341. Knight K., Wade S., Balducci L. Prevalence and outcomes of anemia in cancer: a systematic review of the literature. Am J Med 2004, 116(Suppl. 7A):11S-26S.
342. Gasche C., Dejaco C., Waldhoer T., Tillinger W., Reinisch W., Fueger G.F., et al. Intravenous iron and erythropoietin for anemia associated with Crohn disease. A randomized, controlled trial. Ann Intern Med 1997, 126:782-787.
343. Lindgren S., Wikman O., Befrits R., Blom H., Eriksson A., Granno C., et al. Intravenous iron sucrose is superior to oral iron sulphate for correcting anaemia and restoring iron stores in IBD patients: a randomized, controlled, evaluator-blind, multicentre study. Scand J Gastroenterol 2009, 44:838-845.
344. Schroder O., Mickisch O., Seidler U., de Weerth A., Dignass A.U., Herfarth H., et al. Intravenous iron sucrose versus oral iron supplementation for the treatment of iron deficiency anemia in patients with inflammatory bowel disease-a randomized, controlled, open-label, multicenter study. Am J Gastroenterol 2005, 100:2503-2509.
345. Moreno Lopez R., Sicilia Aladren B., Gomollon Garcia F. Use of agents stimulating erythropoiesis in digestive diseases. World J Gastroenterol 2009, 15:4675-4685.
346. Koutroubakis I.E., Karmiris K., Makreas S., Xidakis C., Niniraki M., Kouroumalis E.A. Effectiveness of darbepoetin-alfa in combination with intravenous iron sucrose in patients with inflammatory bowel disease and refractory anaemia: a pilot study. Eur J Gastroenterol Hepatol 2006, 18:421-425.
347. Phrommintikul A., Haas S.J., Elsik M., Krum H. Mortality and target haemoglobin concentrations in anaemic patients with chronic kidney disease treated with erythropoietin: a meta-analysis. Lancet 2007, 369:381-388.
348. Singh A.K. Resolved: targeting a higher hemoglobin is associated with greater risk in patients with CKD anemia: pro. J Am Soc Nephrol 2009, 20:1436-1441.
349. Alter H.J., Klein H.G. The hazards of blood transfusion in historical perspective. Blood 2008, 112:2617-2626.
350. Khorana A.A., Francis C.W., Blumberg N., Culakova E., Refaai M.A., Lyman G.H. Blood transfusions, thrombosis, and mortality in hospitalized patients with cancer. Arch Intern Med 2008, 168:2377-2381.
351. Jensen L.S., Puho E., Pedersen L., Mortensen F.V., Sorensen H.T. Long-term survival after colorectal surgery associated with buffy-coat-poor and leucocyte-depleted blood transfusion: a follow-up study. Lancet 2005, 365:681-682.
352. Garcia-Erce J.A., Gomollon F., Munoz M. Blood transfusion for the treatment of acute anaemia in inflammatory bowel disease and other digestive diseases. World J Gastroenterol 2009, 15:4686-4694.